Biotechs Expand Into Small Molecules For Drug Discovery
Main Category: Biology / Biochemistry News
Article Date: 03 Nov 2006 - 12:00pm (PST)
Biotech companies traditionally focus on large proteins in their quest to find new drugs. But faced with the complex nature of disease, these companies are increasingly turning to small molecules as well. This new push into small-molecule drug design, which researchers hope will deliver better and more effective disease treatments, is explored in a report scheduled for the Oct. 30 issue of Chemical & Engineering News, the ACS's weekly newsmagazine.
Associate Editor Lisa M. Jarvis describes how major biotech companies such as Genentech and Amgen have moved into the small-molecule arena and expanded their chemistry operations in the process, including new partnerships with drug discovery firms. These efforts have increasingly brought together chemists from a wide range of disciplines, including medicinal, computational and process chemistry, Jarvis writes.
Biotech's investment in small-molecule research is starting to pay off in the form of new drugs, she notes. A few companies already have commercialized new small-molecule drugs for the treatment of lung cancer and kidney disease, while drugs for multiple sclerosis, Parkinson's and other diseases are making their way through the pipeline. By combining small-molecule approaches with protein research, biotech companies are boosting their odds of producing more effective treatments for some of our most challenging diseases, according to the article.
ARTICLE #5
"Biotechs take a more agnostic approach to drug discovery by expanding into small molecules"
FOR FULL TEXT CONTACT:
Michael Bernstein
ACS News Service
Small molecule research
A board to discuss future MS therapies in early stage (Phase I or II) trials.
- scoobyjude
- Family Elder
- Posts: 517
- Joined: Sat Feb 18, 2006 3:00 pm
- Location: suburb of Chicago, IL USA
- Contact:
Jump to
- Multiple Sclerosis
- ↳ General Discussion
- ↳ Introductions
- ↳ Drug Pipeline
- ↳ Regimens
- ↳ Undiagnosed
- ↳ MS Etiology and Pathogenesis
- Treatments
- ↳ Chronic Cerebrospinal Venous Insufficiency (CCSVI)
- ↳ Low Dose Naltrexone
- ↳ Tysabri (Antegren, Natalizumab)
- ↳ Copaxone
- ↳ Glatopa
- ↳ Avonex
- ↳ Rebif
- ↳ Betaseron
- ↳ Plegridy
- ↳ Novantrone
- ↳ Aimspro
- ↳ Diet
- ↳ Stem Cells
- ↳ Antibiotics
- ↳ Campath (Lemtrada, Alemtuzumab)
- ↳ Gene Therapy
- ↳ Natural Approach
- ↳ Biotin (Qizenday, Cerenday, MD1003)
- ↳ Coimbra High-Dose Vitamin D Protocol
- ↳ Statins
- ↳ Tcelna (Tovaxin)
- ↳ Revimmune (Cyclophosphamide, Cytoxan)
- ↳ Medical Devices
- ↳ Rituxan (Rituximab)
- ↳ Ocrevus (Ocrelizumab)
- ↳ Kesimpta (Ofatumumab)
- ↳ Briumvi (Ublituximab-xiiy)
- ↳ General Medications
- ↳ Tecfidera (BG-12, Dimethyl fumarate)
- ↳ Vumerity (Diroximel fumarate)
- ↳ Bafiertam (Monomethyl fumarate)
- ↳ Gilenya
- ↳ Aubagio (Teriflunomide)
- ↳ Mayzent (Siponimod)
- ↳ Zeposia (Ozanimod)
- ↳ Ponvory (Ponesimod)
- ↳ Mavenclad (Cladribine)
- ↳ Ampyra (Dalfampridine)
- ↳ Medical Marijuana
- ↳ Sativex
- ↳ Chiropractic Treatment
- Life
- ↳ Daily Life
- ↳ Veterans and MS
- ↳ Trigeminal Neuralgia in MS
- ↳ Reading Nook
- ↳ Humor
- ↳ Shopping
- ↳ Friends and Family
- ↳ Mental & Spiritual Health
- ↳ Exercise and Physical Therapy
- ↳ Under 25 with MS
- ↳ MS in the Golden Years
- ↳ Parenting Kids With MS
- ↳ Parents with MS
- ThisIsMS.com
- ↳ Site Support
- ↳ Suggestions